Status:
COMPLETED
Evaluating the Analytical Equivalency of Serum and Whole Blood Samples Run on the MeMed Key® Platform (Perseverance Study)
Lead Sponsor:
MeMed Diagnostics Ltd.
Conditions:
Acute Infection
Eligibility:
All Genders
90+ years
Brief Summary
This is a Prospective, multi-center, sample collection study enrolling pediatric and adult subjects presented to the ED/Urgent care, with symptoms consistent with acute bacterial or viral infection wi...
Eligibility Criteria
Inclusion
- Written informed consent must be obtained from the patient or his/her legal guardian. For children under 18 years old, written informed consent from the legal guardian must be obtained and assent from the patient may be required depending on the local requirements.
- Over 90 days of age.
- Clinical suspicion of acute bacterial or viral infection.
- Symptoms of acute infectious disease \< 7 days.
- Experienced fever at least once within the last 7 days (self-reported or Temperature ≥ 37.8°C (100°F)).
Exclusion
- HIV, HBV, active HCV, or active Tuberculosis infection (self-declared or known from medical records).
- Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis.
- Active inflammatory disease (e.g., IBD, SLE, JIA, RA, Kawasaki, other vasculitis).
- Pregnancy- self reported or medically confirmed.
- Active malignancy.
- Congenital or acquired immune deficiency (CID).
- A proven or suspected infection on presentation with Mycobacterial (e.g., Tuberculosis, MAC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen.
- Significant trauma or burns in the last 7 days.
- Patients that have undergone major surgery in the last 7 days.
- Current treatment with immune-suppressive or immune-modulating therapies, including without limitations:
- Administration of P.O.\\IV\\IM high dose steroids \>1mg/kg/day prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids \> 0.25 mg/kg/day in the past 7 days
- Monoclonal antibodies, anti-TNF agents
- Intravenous immunoglobulin (IVIG)
- Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate
- G/GM-CSF, Interferons.
Key Trial Info
Start Date :
February 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 29 2023
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT05439551
Start Date
February 11 2022
End Date
September 29 2023
Last Update
October 24 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Maimonides Medical Center
Brooklyn, New York, United States, 11219
2
Urgent Care Clinical Trials @ AFC Urgent Care- Easley
Easley, South Carolina, United States, 29640
3
Hillel Yaffe Medical Center
Hadera, Israel
4
Carmel Medical Center
Haifa, Israel